Lorcaserin
Sources
registry, as of 2017-06-06Stale
https://clinicaltrials.gov/study/NCT03799198
Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity. Overall status COMPLETED. Phases PHASE4. Lead sponsor Novo Nordisk A/S. Enrollment 200. Conditions Obesity. Researchers are doing this study to compare the effects of drugs approved for long-term weight loss combined with an employer-based weight management program with the effects of the weight management program without drugs for weight loss. If participants agree to be in this study
ClinicalTrials.gov NCT03799198 protocol and results modules
registry, as of 2024-03-27Stale
https://clinicaltrials.gov/study/NCT03353220
Predictors of Lorcaserin-Induced Weight Loss. Overall status TERMINATED. Phases PHASE4. Lead sponsor Columbia University. Enrollment 32. Conditions Overweight and Obesity. This two-phase study aims to explore ways to predict who will respond well to the weight loss drug lorcaserin and to understand the mechanisms that develop which limit drug efficacy. Subjects will be recruited for a 5-week crossover study (phase 1) with lorcaserin and placebo fol
ClinicalTrials.gov NCT03353220 protocol and results modules
registry, as of 2018-06-11Stale
https://clinicaltrials.gov/study/NCT02388568
Lifestyle Modification and Lorcaserin for Weight Loss Maintenance. Overall status COMPLETED. Phases NA. Lead sponsor University of Pennsylvania. Enrollment 137. Conditions Obesity. The proposed 12-month randomized controlled trial will assess the efficacy of lifestyle counseling, combined with lorcaserin (10 mg BID) or placebo, in maintaining weight loss achieved during a prior 14-week dietary run-in. 14-week run-in. To qualify for randomization, participa
ClinicalTrials.gov NCT02388568 protocol and results modules
registry, as of 2019-10-31Stale
https://clinicaltrials.gov/study/NCT03552107
Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic. Overall status COMPLETED. Phases not stated. Lead sponsor Scripps Whittier Diabetes Institute. Enrollment 157. Conditions Obesity; Weight Loss; Overweight. This is a retrospective, descriptive study that involves de-identified data consisting of weight changes, pertinent vital signs and laboratory values influenced by body weight, and healthcare utilization of patients prescribed lorcaserin at The Center for Weight Management at the
ClinicalTrials.gov NCT03552107 protocol and results modules
registry, as of 2019-07-16Stale
https://clinicaltrials.gov/study/NCT02019264
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors. Overall status COMPLETED. Phases PHASE4. Lead sponsor Eisai Inc.. Enrollment 14673. Conditions Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes. This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
ClinicalTrials.gov NCT02019264 protocol and results modules
registry, as of 2017-06-06Stale
https://clinicaltrials.gov/study/NCT02393547
Lorcaserin for Preventing Weight Gain Among Smokers. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor Mayo Clinic. Enrollment 20. Conditions Tobacco Use Disorder; Weight Gain. This will be an open label clinical trial with all subjects receiving both lorcaserin and varenicline with a primary aim of reducing post cessation weight gain.
ClinicalTrials.gov NCT02393547 protocol and results modules
publication, as of 2012-06-05Stale
https://pubmed.ncbi.nlm.nih.gov/31644141/
Lorcaserin is a selective serotonin agonist that was used as a weight loss agent. Lorcaserin was in clinical use for eight years when it was withdrawn because of concerns regarding an excess in cancer risk after long term u
PMID 31644141